Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

0.8351 -0.0309 (-3.57%)
Streaming Delayed Price Updated: 11:50 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,914,648
Open 0.8757
Bid (Size) 0.8343 (400)
Ask (Size) 0.8358 (600)
Prev. Close 0.8660
Today's Range 0.8226 - 0.8800
52wk Range 0.6816 - 7.290
Shares Outstanding 54,291,754
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit

Performance

YTD
-78.6%
-78.6%
1 Month
+7.7%
+7.7%
3 Month
-83.4%
-83.4%
6 Month
-76.7%
-76.7%
1 Year
-72.9%
-72.9%

More News

Read More
Levi & Korsinsky Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYR
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action Lawsuits
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
From The Rosen Law Firm PA
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
From Pomerantz LLP
Via GlobeNewswire
December 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATYR
Via NewMediaWire
Topics Fraud Lawsuit
December 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATYR
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action Lawsuits
From Bragar Eagel & Squire
Via GlobeNewswire
ATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
From Pomerantz LLP
Via GlobeNewswire
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Lost Money on aTyr Pharma, Inc. (ATYR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on aTyr Pharma, Inc. (ATYR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action Lawsuits
From Bragar Eagel & Squire
Via GlobeNewswire
Deadline Approaching: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire

Frequently Asked Questions

Is aTyr Pharma, Inc. - Common Stock publicly traded?
Yes, aTyr Pharma, Inc. - Common Stock is publicly traded.
What exchange does aTyr Pharma, Inc. - Common Stock trade on?
aTyr Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for aTyr Pharma, Inc. - Common Stock?
The ticker symbol for aTyr Pharma, Inc. - Common Stock is ATYR on the Nasdaq Stock Market
What is the current price of aTyr Pharma, Inc. - Common Stock?
The current price of aTyr Pharma, Inc. - Common Stock is 0.8351
When was aTyr Pharma, Inc. - Common Stock last traded?
The last trade of aTyr Pharma, Inc. - Common Stock was at 11/03/25 11:50 AM ET
What is the market capitalization of aTyr Pharma, Inc. - Common Stock?
The market capitalization of aTyr Pharma, Inc. - Common Stock is 45.34M
How many shares of aTyr Pharma, Inc. - Common Stock are outstanding?
aTyr Pharma, Inc. - Common Stock has 45M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.